Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG006 in advanced small cell lung cancer or neuroendocrine carcinoma
CTR20232357Phase 2Active
- Sponsor
- Zelgen
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), Nonhematologic neoplasms, sponsored by Zelgen. Started Oct 2023; status: active.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232357.